J&J reports Phase III CLL, SLL data for Imbruvica combo

Johnson & Johnson (NYSE:JNJ) released data from a Phase III trial showing that patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving Imbruvica ibrutinib plus bendamustine and Rituxan had significantly longer progression-free survival (PFS) than those receiving bendamustine and Rituxan rituximab alone.

In the 578-patient HELIOS trial, median PFS was not yet reached in a study arm receiving Imbruvica plus bendamustine and Rituxan, while a bendamustine/Rituxan control arm had a median PFS of 13.3 months (HR:0.203; 95% CI: 0.150, 0.276; p<0.0001). Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...